World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
46631
World Ranking
11093
National Ranking
5708

Overview

Roy Fleischmann is affiliated with The University of Texas Southwestern Medical Center in the United States and has published extensively in the field of medicine, with a particular focus on rheumatology. Their scholarly work spans across several interconnected medical disciplines including hematology, genetics, pathology and forensic medicine, and immunology.

The scientist's research contributions are notably concentrated on rheumatoid arthritis and related autoimmune and inflammatory disorders. Key topics covered in their body of work include rheumatoid arthritis research and therapies, autoimmune and inflammatory disorders research, systemic lupus erythematosus research, chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, biosimilars and bioanalytical methods, and cytokine signaling pathways and interactions.

Frequent publication venues for Roy Fleischmann include:

  • Annals of the Rheumatic Diseases
  • RMD Open
  • Rheumatology and Therapy
  • Lara D. Veeken
  • Arthritis & Rheumatology

The scientist has collaborated regularly with a number of peers in the field. Frequent coauthors include:

  • Yoshiya Tanaka
  • Eduardo Mysler
  • Josef S Smolen
  • Tsutomu Takeuchi
  • Peter C. Taylor

Among the notable publications, the following represent some of the scientist's recent and influential papers:

  • Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study, 2022, RMD Open
  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Respiratory Medicine
  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, 2020, Annals of the Rheumatic Diseases
  • Infections in baricitinib clinical trials for patients with active rheumatoid arthritis, 2020, Annals of the Rheumatic Diseases
  • Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician, 2024, Nature Reviews Rheumatology

Best Publications

  • A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

    Michael E. Weinblatt;Joel M. Kremer;Arthur D. Bankhurst;Ken J. Bulpitt

  • A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

    Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann;John R. Tesser

  • Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

    Larry W. Moreland;Scott W. Baumgartner;Michael H. Schiff;Elizabeth A. Tindall

  • Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial

    Larry W. Moreland;Michael H. Schiff;Scott W. Baumgartner;Elizabeth A. Tindall

  • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

    Paul Emery;Roy Fleischmann;Anna Filipowicz-Sosnowska;Joy Schechtman

  • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

    Ronald F. van Vollenhoven;Roy Fleischmann;Stanley Cohen;Eun Bong Lee

  • Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

    D. E. Furst;E. C. Keystone;J. Braun;F. C. Breedveld

  • Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

    Roy Fleischmann;Joel Kremer;John Cush;Hendrik Schulze-Koops

  • Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate

    Vibeke Strand;Stanley Cohen;Michael Schiff;Arthur Weaver

  • Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.

    Mark C. Genovese;Joan M. Bathon;Richard W. Martin;Roy M. Fleischmann

  • Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.

    John C. Davis;Désirée Van Der Heijde;Jurgen Braun;Maxime Dougados

  • Tofacitinib versus Methotrexate in Rheumatoid Arthritis

    Eun-Bong Lee;Roy M Fleischmann;Stephen Hall;Bethanie E Wilkinson

  • Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).

    Daniel E Furst;Michael H Schiff;Roy M Fleischmann;Vibeke Strand

  • Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

    Désirée van der Heijde;Yoshiya Tanaka;Roy Fleischmann;Edward Keystone

  • Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

    Dinesh Khanna;Celia J F Lin;Daniel E Furst;Jonathan Goldin

  • Etanercept Therapy in Rheumatoid Arthritis

    Larry W. Moreland;Michael H. Schiff;Scott W. Baumgartner;Elizabeth A. Tindall

  • Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).

    P J Mease;R Fleischmann;A A Deodhar;J Wollenhaupt

  • Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

    Paul Emery;Roy M. Fleischmann;Larry W. Moreland;Elizabeth C. Hsia

  • Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate: Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year

    Joel M. Kremer;Ricardo Blanco;Marek Brzosko;Ruben Burgos-Vargas

  • Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial.

    Roy M. Fleischmann;Joy Schechtman;Ralph Bennett;Malcolm L. Handel

Frequent Co-Authors

Mark C. Genovese
Mark C. Genovese Stanford University
Paul Emery
Paul Emery University of Leeds
Michael E. Weinblatt
Michael E. Weinblatt Brigham and Women's Hospital
Désirée van der Heijde
Désirée van der Heijde Leiden University Medical Center
Daniel E. Furst
Daniel E. Furst University of California, Los Angeles
Edward C. Keystone
Edward C. Keystone University of Toronto
Josef S. Smolen
Josef S. Smolen Medical University of Vienna
Ronald F. van Vollenhoven
Ronald F. van Vollenhoven University of Amsterdam
Joel M. Kremer
Joel M. Kremer Albany Medical Center Hospital
Stanley Cohen
Stanley Cohen The University of Texas Southwestern Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Looking to expand your career options beyond traditional medical school? A variety of flexible, reputable online programs can help you move forward in the healthcare field. Many professionals consider advanced degrees like a Master of Health Administration. For those interested in leadership roles, top cahme-accredited mha programs provide robust training in healthcare management and policy—entirely online.

Registered nurses aiming to increase their qualifications can benefit from convenient pathways as well. The rn to bsn online with no clinicals options enable nurses to earn a bachelor’s degree without additional clinical requirements, accelerating their education while balancing work.

For nurses pursuing the highest levels of clinical expertise, Doctor of Nursing Practice programs have become more accessible than ever. Explore accelerated dnp programs designed for rapid skill advancement, or consider the cheapest dnp programs to achieve your goals affordably.

Whether you seek management, advanced nursing, or a bridge to new roles, these online degree pathways offer flexible solutions for a changing healthcare landscape.

Best Scientists Citing Roy Fleischmann

Trending Scientists